Celecoxib to decrease urinary retention associated with prostate brachytherapy.
OBJECTIVE
To retrospectively evaluate the effect of celecoxib in preventing urinary retention following prostate brachytherapy.


METHODS
Between December 1997 and November 2001, 149 patients underwent a prostate implant. Medical records were reviewed to identify those who had acute urinary retention after the procedure. Urinary retention was scored based on replacement of the urinary catheter and the number of calls to the clinic and/or unscheduled clinic visits within 1 month after the implant.


RESULTS
The use of celecoxib was associated with a decreased need for replacement of the catheter (p=.04) and decreased number of calls to the clinic and/or unscheduled clinic visits (p=.002). No patient who was given celecoxib for 1 week before brachytherapy required a urinary catheter compared to 14 (of 120) who did not receive celecoxib.


CONCLUSIONS
The use of celecoxib appears to result in decreased urinary retention following prostate brachytherapy.
Feigenberg
Steven J
SJ
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Wolk
Kellie L
KL
Yang
Chin-Huey
CH
Morris
Christopher G
CG
Zlotecki
Robert A
RA
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001918:Brachytherapy / Q000009:adverse effects* / Q000379:methods*; D000068579:Celecoxib; D005549:Foreign-Body Reaction / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D019736:Prostheses and Implants / Q000009:adverse effects*; D011720:Pyrazoles; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib